黑色素瘤的预后生物标志物：为患者量身定制治疗方案。
Prognostic Biomarkers in Melanoma: Tailoring Treatments to the Patient.
作者信息
Safai Bijan, Wu Albert G, Hamby Carl V
机构信息
Dr. Safai is with the Department of Dermatology, Metropolitan Hospital in New York, New York.
Mr. Wu and Dr. Hamby are with New York Medical College School of Medicine in Valhalla, New York.
出版信息
J Clin Aesthet Dermatol. 2021 Dec;14(12):44-48.
BACKGROUND
It is often difficult to accurately predict how a melanoma will progress because melanomas can be so diverse in their genetic and histological makeup.
OBJECTIVE
We sought to characterize the current state and progression of biomedical markers towards their utilization as prognostic indicators for patients with melanoma.
METHODS
A literature search of the research repository databases PubMed and GoogleScholar was conducted using the following inclusion criteria: (1) published within the last 10 years, and (2) use of overall survival, disease progression, or clinical outcome as primary endpoints. Search terms included various permutations of "biomarkers," "prognostic," "immunologic," "serologic," "visual," and "melanoma." Results were evaluated for statistical power, results significance, and experimental design integrity.
RESULTS
The prognostic capabilities of clinical tests for malignant melanoma have made great strides in the last few years, with several serologic and immunohistochemical biomarkers being preliminarily linked to various measures of clinical prognosis. While clinical feasibility of a single sensitive and specific biomarker remains unfeasible, use of select combinations of tested biomarkers remain viable.
CONCLUSION
Diagnostic and prognostic genetic assays have begun to cross over from research to commercial application, giving physicians additional tools during the early stages of diagnosis to optimize and individualize treatments.
背景
由于黑色素瘤在基因和组织构成上具有多样性，准确预测其发展进程往往困难重重。
目的
我们旨在描述生物医学标志物的当前状况及其作为黑色素瘤患者预后指标的应用进展。
方法
使用以下纳入标准对研究数据库PubMed和GoogleScholar进行文献检索：（1）过去10年内发表；（2）以总生存期、疾病进展或临床结局作为主要终点。检索词包括“生物标志物”“预后”“免疫的”“血清学的”“视觉的”和“黑色素瘤”的各种排列组合。对结果进行统计功效、结果显著性和实验设计完整性评估。
结果
在过去几年中，恶性黑色素瘤临床试验的预后能力取得了长足进步，一些血清学和免疫组化生物标志物已初步与各种临床预后指标相关联。虽然单一敏感且特异的生物标志物在临床上仍不可行，但使用经过测试的生物标志物的特定组合仍然可行。
结论
诊断和预后基因检测已开始从研究转向商业应用，为医生在诊断早期提供了更多工具，以优化治疗并实现个性化治疗。
Zotero 插件